Si-bone, inc. SIBN.US Overview
SIBN AI Analysis & Strategy
Analysis Conclusion
The stock, with its moderate value rating, suggests that existing positions can be retained. For initiating new positions, it's advisable to wait for a value score above 4 and a dividend score of 2 or higher.
SIBN Current Performance
1.88%
Si-bone, inc.
-1.19%
Avg of Sector
0.52%
S&P500
SIBN Key Information
SIBN Financial Forecast
Unit : USD
SIBN Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | -0.15 | 44.4% | -37.5% | 47.29M | 24.9% | 1.2% | -9.2% |
| 2024Q3 | -0.11 | 59.3% | -24.4% | 49M | 26.1% | 1.8% | -16.3% |
| 2024Q2 | -0.16 | 36% | -27.3% | 40.34M | 18.6% | -14% | -22.4% |
| 2024Q1 | -0.22 | 26.7% | -15.4% | 39.97M | 20% | 4.3% | -28.8% |
| 2023Q4 | -0.27 | 15.6% | -6.9% | 37.87M | 15.8% | 3.8% | -28.3% |
SIBN Profile
SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.